Deescalating Adjuvant Trastuzumab in HER2-Positive Early-Stage Breast Cancer: A Systemic Review and Meta-Analysis

BACKGROUND: One year of adjuvant trastuzumab in combination with chemotherapy is the standard of care in early-stage human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Existing data on shortening trastuzumab treatment show conflicting results. METHODS: A search of PubMed and abs...

Descripción completa

Detalles Bibliográficos
Autores principales: Goldvaser, Hadar, Korzets, Yasmin, Shepshelovich, Daniel, Yerushalmi, Rinat, Sarfaty, Michal, Ribnikar, Domen, Thavendiranathan, Paaladinesh, Amir, Eitan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6649709/
https://www.ncbi.nlm.nih.gov/pubmed/31360906
http://dx.doi.org/10.1093/jncics/pkz033

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6649709/
https://www.ncbi.nlm.nih.gov/pubmed/31360906
http://dx.doi.org/10.1093/jncics/pkz033

Ejemplares similares